Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 395

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 395
---
2022.

A 10% decline in stock prices of the quoted equity investments included within “Equity instruments at fair value

through other comprehensive income” would have had a pre-tax impact of € 47million on Other comprehensive income as

of December 31, 2024 .

Unquoted equity instruments

The line item “Equity instruments at fair value through other comprehensive income” also includes equity investments not quoted

in an active market with a carrying amount of € 1,092million as of December 31, 2024 , € 618million as of December 31, 2023

and € 549million as of December 31, 2022 .

The change in unquoted equity investments included in the “Equity instruments at fair value through other comprehensive

income” category during the year ended December 31, 2024 was mainly due to an investment in EUROAPI in the form of a

perpetual subordinated hybrid bond of which the value at inception date was € 200million and the value as of December 31,

2024 is € 189million , and various equity stakes acquired through the Sanofi Ventures fund.

In addition, commitments relating to equity investments classified in this asset category amounted to € 360million as of

December 31, 2024 (versus € 65million as of December 31, 2023). The figure as of December 31, 2024 includes € 300million

relating to an equity interest of approximately 16% in Orano Med, a new entity valued at € 1.9billion focused on the discovery,

design, and clinical development of next-generation radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting

isotopes.

| SANOFIFORM 20-F2024 | F-47 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

D.7.2. Debt instruments at fair value through other comprehensive income The “Debt instruments at fair value through other comprehensive income” category includes quoted euro-denominated senior bonds amounting to € 357million as of December 31, 2024 , including € 110million of securities obtained in exchange for financial assets held to meet obligations to employees under post-employment benefit plans. Sanofi held € 346million of quoted senior bonds as of December 31, 2023 and € 329million as of December 31, 2022 . As regards debt